Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?

被引：1
|
作者：
Calvo Romero, J. M. [1 ]
机构：
[1] Hosp Ciudad Coria, Med Interna Serv, Coria, Caceres, Spain
来源：
REVISTA CLINICA ESPANOLA | 2011年 / 211卷 / 03期
关键词：
Dabigatran; Direct thrombin inhibitor; Vitamin K antagonist; Atrial fibrillation; INTERNATIONAL NORMALIZED RATIO; DIRECT THROMBIN INHIBITOR; ORAL ANTICOAGULATION; RISK STRATIFICATION; PREDICTING STROKE; GENERAL-PRACTICE; WARFARIN; THERAPY; MANAGEMENT; ETEXILATE;
D O I：
10.1016/j.rce.2010.12.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with atrial fibrillation (AF) at risk of stroke are not always anticoagulated with vitamin K antagonists (VKA) despite lack of contraindication. Dabigatran, an oral direct thrombin inhibitor, is a new option with proven safety and effectiveness in these patients. The advantages of dabigatran are its more predictable response, obviating coagulation monitoring and possible lower frequency of bleedings. Its drawbacks are cost, lack of antidote and long-term data, frequency of dyspepsia and the twice daily dosage. (C) 2011 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：142 / 146
页数：5
相关论文
共 50 条
  • [1] Dabigatran for the prevention of stroke in patients with atrial fibrillation
    Diener, Hans-Christoph
    Weber, Ralph
    Weimar, Christian
    Frank, Benedikt
    Kirchhof, Paulus
    PSYCHOPHARMAKOTHERAPIE, 2011, 18 (04): : 156 - +
  • [2] Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
    Chevalier, Julie
    Delaitre, Olivier
    Hammes, Florence
    de Pouvourville, Gerard
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2014, 107 (6-7) : 381 - 390
  • [3] Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
    Kozlowski, Dariusz
    Budrejko, Szymon
    Raczak, Grzegorz
    Rysz, Jacek
    Banach, Maciej
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (21) : 3816 - 3826
  • [4] Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists
    Barrios, Vivencio
    Escobar, Carlos
    Jose Gomez-Doblas, Juan
    Fernandez-Duenas, Jaime
    Romero Garrido, Rafael
    Pindado Rodriguez, Javier
    Umaran Sanchez, Juana
    Arellano-Rodrigo, Eduardo
    Donado, Esther
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (09) : 615 - 625
  • [5] Dabigatran for stroke prevention in atrial fibrillation
    Hohnloser, S. H.
    Diener, H. -C.
    HAMOSTASEOLOGIE, 2012, 32 (03): : 216 - 220
  • [6] Dabigatran for Stroke Prevention in Patients with TIA or Ischaemic Stroke and Atrial Fibrillation: Practical Apects
    Diener, H. C.
    Grond, M.
    Roether, J.
    Veltkamp, R.
    Weber, R.
    Weimar, C.
    Hohnloser, S. H.
    AKTUELLE NEUROLOGIE, 2011, 38 (05) : 261 - 266
  • [7] Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
    Pletscher, Mark
    Plessow, Rafael
    Eichler, Klaus
    Wieser, Simon
    SWISS MEDICAL WEEKLY, 2013, 143
  • [8] Dabigatran for Stroke Prevention in All Patients with Atrial Fibrillation?
    Hunchuck, Jonathan E.
    Lake, Jennifer D.
    PHARMACOTHERAPY, 2011, 31 (08): : 725 - 728
  • [9] Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Rocha, Evangelista
    Ferreira, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2013, 32 (7-8) : 557 - 565
  • [10] Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
    Huisman, Menno V.
    Lip, Gregory Y. H.
    Diener, Hans-Christoph
    Brueckmann, Martina
    van Ryn, Joanne
    Clemens, Andreas
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 838 - 847
12345